JP2021501566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501566A5 JP2021501566A5 JP2020518692A JP2020518692A JP2021501566A5 JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5 JP 2020518692 A JP2020518692 A JP 2020518692A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- amino acid
- antibody
- acid sequence
- transmembrane domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186940A JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566936P | 2017-10-02 | 2017-10-02 | |
| US62/566,936 | 2017-10-02 | ||
| US201862725880P | 2018-08-31 | 2018-08-31 | |
| US62/725,880 | 2018-08-31 | ||
| PCT/US2018/053989 WO2019070726A1 (en) | 2017-10-02 | 2018-10-02 | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Division JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501566A JP2021501566A (ja) | 2021-01-21 |
| JP2021501566A5 true JP2021501566A5 (https=) | 2021-11-11 |
Family
ID=63966111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518692A Pending JP2021501566A (ja) | 2017-10-02 | 2018-10-02 | Ｃｄ１３８に対する抗体分子およびその使用 |
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11945868B2 (https=) |
| EP (1) | EP3692069A1 (https=) |
| JP (2) | JP2021501566A (https=) |
| KR (1) | KR20200058540A (https=) |
| CN (2) | CN111183157A (https=) |
| AU (1) | AU2018345637A1 (https=) |
| BR (1) | BR112020005419A2 (https=) |
| CA (1) | CA3074032A1 (https=) |
| IL (2) | IL320863A (https=) |
| MX (1) | MX2020003783A (https=) |
| MY (1) | MY205689A (https=) |
| PH (1) | PH12020550141A1 (https=) |
| SG (1) | SG11202002248TA (https=) |
| WO (1) | WO2019070726A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110691793A (zh) * | 2017-04-26 | 2020-01-14 | 田边三菱制药株式会社 | 黏结蛋白聚糖-1（cd138）结合剂及其用 |
| MX2020003783A (es) | 2017-10-02 | 2021-01-08 | Visterra Inc | Moleculas de anticuerpo de cd138 y sus usos. |
| CA3142021A1 (en) * | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| CA3147757A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| KR20220092578A (ko) * | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| US20240319194A1 (en) * | 2021-06-29 | 2024-09-26 | Sheba Impact Ltd. | Diagnosis and treatment of pancreatic cancer |
| CN113514645A (zh) * | 2021-07-13 | 2021-10-19 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | CD138抗体联合Mum1抗体在检测浆细胞中的应用 |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| CN115120725B (zh) * | 2022-05-30 | 2023-11-07 | 南方医科大学 | Sdc1作为骨质破坏疾病药物治疗靶点的应用 |
| CN115960231A (zh) * | 2022-09-28 | 2023-04-14 | 合肥天港免疫药物有限公司 | 抗cd138的抗体及其应用 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP1356093A2 (en) | 2000-06-21 | 2003-10-29 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| CA2486285C (en) | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| US20070054332A1 (en) * | 2005-08-10 | 2007-03-08 | Alan Rapraeger | Syndecan 1 ectodomain inhibits cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2710453C (en) | 2007-12-26 | 2019-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
| ES2526433T3 (es) | 2007-12-26 | 2015-01-12 | Biotest Ag | Inmunoconjugados dirigidos a CD138 y usos de los mismos |
| EP2240516B1 (en) * | 2007-12-26 | 2015-07-08 | Biotest AG | Methods and agents for improving targeting of cd138 expressing tumor cells |
| JP2011507933A (ja) | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
| NZ613647A (en) | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US9249467B2 (en) | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
| US10577543B2 (en) | 2011-10-27 | 2020-03-03 | Raymond Roger Wallage | Efficient oil shale recovery method |
| MX358680B (es) | 2011-12-08 | 2018-08-31 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
| KR101721678B1 (ko) | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 |
| GB201216002D0 (en) | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CN103103197A (zh) | 2013-01-30 | 2013-05-15 | 百奇生物科技（苏州）有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
| RU2611685C2 (ru) | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| MX2020003783A (es) | 2017-10-02 | 2021-01-08 | Visterra Inc | Moleculas de anticuerpo de cd138 y sus usos. |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| CN114144437B (zh) | 2019-06-07 | 2025-02-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| CA3142021A1 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
-
2018
- 2018-10-02 MX MX2020003783A patent/MX2020003783A/es unknown
- 2018-10-02 CN CN201880064634.XA patent/CN111183157A/zh active Pending
- 2018-10-02 SG SG11202002248TA patent/SG11202002248TA/en unknown
- 2018-10-02 MY MYPI2020001188A patent/MY205689A/en unknown
- 2018-10-02 WO PCT/US2018/053989 patent/WO2019070726A1/en not_active Ceased
- 2018-10-02 IL IL320863A patent/IL320863A/en unknown
- 2018-10-02 KR KR1020207012740A patent/KR20200058540A/ko not_active Ceased
- 2018-10-02 JP JP2020518692A patent/JP2021501566A/ja active Pending
- 2018-10-02 CN CN202411128002.9A patent/CN119192374A/zh active Pending
- 2018-10-02 IL IL273572A patent/IL273572B2/en unknown
- 2018-10-02 EP EP18793101.9A patent/EP3692069A1/en active Pending
- 2018-10-02 US US16/149,854 patent/US11945868B2/en active Active
- 2018-10-02 BR BR112020005419-4A patent/BR112020005419A2/pt not_active Application Discontinuation
- 2018-10-02 AU AU2018345637A patent/AU2018345637A1/en not_active Abandoned
- 2018-10-02 CA CA3074032A patent/CA3074032A1/en active Pending
-
2020
- 2020-03-26 PH PH12020550141A patent/PH12020550141A1/en unknown
-
2023
- 2023-10-31 JP JP2023186940A patent/JP2024001294A/ja active Pending
-
2024
- 2024-02-20 US US18/581,992 patent/US20240301065A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501566A5 (https=) | ||
| JP7179464B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| AU2010292342C1 (en) | High affinity human antibodies to human protease-activated receptor-2 | |
| JP2020115876A (ja) | Ｐｄ−ｌ１に対するヒト抗体 | |
| US11945868B2 (en) | Antibody molecules to CD138 and uses thereof | |
| JP2023516936A (ja) | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 | |
| CN106068275A (zh) | 抗pd‑1的人抗体 | |
| TW201006493A (en) | Compositions and methods of use for therapeutic antibodies | |
| WO2020198370A2 (en) | Therapeutic cd47 antibodies | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| JP2025041695A (ja) | 抗体および使用方法 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| JP2026021532A (ja) | Ｂｔｌａ抗体 | |
| CA3207703A1 (en) | Anti-s100a4 humanized antibodies, uses and methods | |
| JP2024097985A (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| AU2018361819A1 (en) | Antibodies and methods of use | |
| US20250051473A1 (en) | Anti-cd38 binding molecules and uses thereof | |
| EP3898694A1 (en) | Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof | |
| CN114641500A (zh) | 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法 | |
| CN118679185A (zh) | 抗cd38结合分子及其用途 | |
| CA3250219A1 (en) | ANTIBODIES AGAINST BTLA AND THEIR USES | |
| HK40074321A (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies | |
| HK40114352A (zh) | 针对btla的抗体及其用途 | |
| EA050239B1 (ru) | Мультиспецифические антитела, связывающиеся с bcma | |
| EA048356B1 (ru) | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |